Market LIVE
Published markets; coverage varies by country
Product profile · United States

PEMAZYRE

 ·  Patent Litigation & Settlement History ↓

IngredientPEMIGATINIB
Application typeNDA
Application213736
Product002
Dosage formTABLET
RouteORAL
Strength9MG
Approval date2020-04-17
Marketing statusPrescription
Status event—
ApplicantINCYTE CORP
Product source

Current GenericRadar decision

Year2035
SelectionDEEP_REVIEW
ReviewFINAL
Anchor typeTRUE_DS_PATENT
Anchor date2035-01-30
Patent anchor2035-01-30
Exclusivity anchor2029-08-26
Protection date—
First Final ANDA—
Status event—

QUALIFYING_ANCHOR_WITH_LATER_RIGHTS; ; Full approved-scope combination maximum date confirmed.

Patent estate

PatentEffective dateOfficial listingTRUE_DSDS gradeClaim classification / basisPTEPEDFamily
101316672034-04-17U U-2809———
———
96112672035-01-30DS/DP ————
———
114660042039-05-03U U-3466———
———
114660042039-05-03U U-3464———
———
114660042039-05-03U U-3465———
———
116281622040-08-30U U-3570———
———
116281622040-08-30U U-3569———
———
116281622040-08-30U U-3571———
———
116281622040-08-30U U-3568———
———
125527922040-10-03DS/DP ————
———

Regulatory exclusivity

CodeStart dateEnd dateScopeEntire productAll indicationsFull coverage dateCombinationSource
ODE-292—2027-04-17————Source
ODE-404—2029-08-26————Source

2026-10-10 · CURRENT_SOURCE_RECORDS_FOUND · Historical coverage: NOT_COMPLETE

Generic approval evidence

Application / productEventFinal dateTentative dateApplicantAuthorized genericExact mappingSource
No generic approval facts are linked to this product.

Market Entry Information

API filings, authorized generics and linked regulatory milestones.

API Master Files & Certifications 0 records

Ingredient-level registrations from linked public manufacturer portfolios. A filing does not establish supply to this finished product. DMFs are not FDA approvals.

APIHolder / manufacturerHolder countryFiling typeNumberStatusFiled dateAvailable for referenceSourceLast verified
No master-file or certification records are linked through public manufacturer portfolios.

Authorized Generics 0 records

Authorized generics are shown separately from independent ANDA approvals.

Application / productApplicantEvent / status First marketed Product mappingSourceLast verified
No authorized-generic records are linked to this product.

Tentative ANDA Approvals 0 records

Tentative approval is not final approval. Historical tentative approvals remain visible after a linked final approval.

Application / productApplicantEvent / status Tentative date Follow-up final approvalProduct mappingSourceLast verified
No tentative-approval records are linked to this product.

Paragraph IV Challenges 0 records

Paragraph IV challenges below are sourced from legal records separately from FDA approvals. An ANDA filing, lawsuit or settlement does not establish final approval or commercial launch.

Application / productApplicantEvent / status Certification event date Product mappingSourceLast verified
No structured Paragraph IV certification events are linked in the available approval evidence.

Final ANDA Approvals 0 records

Approval dates do not establish commercial launch. Product mapping is shown for each linked record.

Application / productApplicantEvent / status Final approval date Product mappingSourceLast verified
No final-approval records are linked to this product.
Independent legal-event information

Litigation & Settlement History

Settlement launch rights generally apply only to the named parties and product scope. These records do not change GenericRadar patent/exclusivity anchors or current decisions.

No litigation or settlement record currently linked to this product.